Under this circumstance, DM patients might have higher platelet inhibition leading to reduced platelet reactivity, which increases the risk of a bleeding event.[25] Third, the DM patients had been experiencing platelet hyperactivity for a long time, but they were more likely to be treated with hypoglycemic agents before AMI, which may decrease coagulability due to the reduced production of thromboxane A and plasminogen activator inhibitor 1 activity. This evidence concerns the gene SERPINE1 and diabetes mellitus.